Home

Insights

PE

Concord Drugs Ltd P/E Ratio

Concord Drugs Ltd P/E Ratio

download
stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

1.4 K

stocks traded

Last Updated time: 14 Jul 15:30 PM

Image

Concord Drugs Ltd

NSE: CONCORDDRUGS

PE

82.2

Last updated : 14 Jul 15:30 PM

Key Highlights

    The P/E Ratio of Concord Drugs Ltd is 82.2 as of 14 Jul 15:30 PM .a1#The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 25.9 on March 2023 . This represents a CAGR of 27.63% over 2 years. a1#The Latest Trading Price of Concord Drugs Ltd is ₹ 38.64 as of 12 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.7. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Pharmaceuticals industry is 35.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 24 crore on March 2023 . This represents a CAGR of -2.72% over 2 years. a1#The Revenue of Concord Drugs Ltd changed from ₹ 12.54 crore to ₹ 15.64 crore over 8 quarters. This represents a CAGR of 11.68% a1#The EBITDA of Concord Drugs Ltd changed from ₹ 0.98 crore to ₹ 0.35 crore over 8 quarters. This represents a CAGR of -40.24% a1#The Net Pr of Concord Drugs Ltd changed from ₹ 0.19 crore to ₹ -0.34 crore over 8 quarters. This represents a CAGR of NaN% a1#The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Concord Drugs Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Concord Drugs Ltd

Period
Mar '2215.9
Mar '2325.9

Company Fundamentals for Concord Drugs Ltd

Market Cap

38 Cr

EPS

0.5

P/E Ratio (TTM) *

82.2

P/B Ratio (TTM) *

1.1

Day’s High

39.58

Day’s Low

38.05

DTE *

0.5

ROE *

1.4

52 Week High

61.5

52 Week Low

25.56

ROCE *

5.0

* All values are consolidated

Last Updated time: 14 Jul 15:30 PM

* All values are consolidated

Last Updated time: 14 Jul 15:30 PM

Image

Concord Drugs Ltd

NSE: CONCORDDRUGS

PRICE

38.64

0.02 (0.05%)

stock direction

Last updated : 12 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

Asset Value vs Market Value of Concord Drugs Ltd

Market Value

39

-0.1 X

Value addition

Asset Value

43

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Concord Drugs Ltd8238
Sun Pharmaceuticals Industries Ltd37378,675
Cipla Ltd28122,093
Divis Laboratories Ltd75120,480
Zydus Lifesciences Ltd30118,217
Dr Reddys Laboratories Ltd20112,137

Key Valuation Metric of Concord Drugs Ltd

Earnings

0 Cr

82.2 X

PE Ratio

Market Cap

₹38.64Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

0 Cr

82.2 X

PE Ratio

Market Cap

₹38.64Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Concord Drugs Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Concord Drugs Ltd

Period
Mar '2225
Mar '2324

* All values are a in crore

×

Historical Revenue of Concord Drugs Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Concord Drugs Ltd

Period
Jun '2213
Sep '2214
Dec '2214
Mar '2312
Jun '239
Sep '238
Dec '2313
Mar '2416

* All values are a in crore

×

Historical EBITDA of Concord Drugs Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Concord Drugs Ltd

Period
Jun '221
Sep '221
Dec '221
Mar '231
Jun '231
Sep '232
Dec '231
Mar '240

* All values are a in crore

×

Historical Net Profit of Concord Drugs Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Concord Drugs Ltd

Period
Jun '220
Sep '220
Dec '220
Mar '230
Jun '230
Sep '231
Dec '230
Mar '240

* All values are a in crore

×

Historical Dividend Payout of Concord Drugs Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Concord Drugs Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

* All values are a in %

About Concord Drugs Ltd

About Concord Drugs Ltd

    Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. It is engaged in developing New products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. It operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products.

Concord Drugs Ltd News Hub

News

Concord Drugs postpones board meeting

Concord Drugs has postponed the meeting of the Board of Directors which was scheduled to b...

Read more

25 May 202411:26

News

Concord Drugs declare Quarterly Result

Concord Drugs will hold a meeting of the Board of Directors of the Company on 25 May 2024 ...

Read more

16 May 202412:41

News

Concord Drugs to announce Quarterly Result

Concord Drugs will hold a meeting of the Board of Directors of the Company on 13 February ...

Read more

07 Feb 202419:05

News

Concord Drugs to conduct board meeting

Concord Drugs will hold a meeting of the Board of Directors of the Company on 14 November ...

Read more

08 Nov 202315:27

News

Concord Drugs to conduct AGM

Concord Drugs announced that the 28th Annual General Meeting (AGM) of the company will be ...

Read more

13 Sep 202310:15

News

Concord Drugs to hold board meeting

Concord Drugs will hold a meeting of the Board of Directors of the Company on 14 August 20...

Read more

09 Aug 202312:43

Product Composition by Percentage (Revenue)

FAQs for PE of Concord Drugs Ltd

What is Concord Drugs Ltd current share price?

The current market price of Concord Drugs Ltd as of July 14, 2024 is ₹38.64.

What is Concord Drugs Ltd's market cap?

Concord Drugs Ltd's market capitalisation stood at ₹38 Cr as of July 14, 2024

What are Concord Drugs Ltd's total net assets?

According to Concord Drugs Ltd's most recent financial filings, the company's net assets total ₹43.5 Cr.

Is Concord Drugs Ltd making a profit or loss?

Concord Drugs Ltd's net Profit as of July 14, 2024 is close to ₹0 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199